Skip to main content

Table 1 Effect of secukinumab on pain by prior TNF exposure through week 104

From: Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study

  Week 3 Week 4 Week 8 Week 16 Week 24 Week 52 Week 104
TNF-naïve
 Pain VAS, mean change from baselinea
  Secukinumab 300 mg −19.7* −20.7** − 20.7* −27.8**** − 24.0 −30.3 −29.6
  Secukinumab 150 mg −12.8 −15.2 −21.8* − 25.1*** −26.3 −28.1 −28.3
  Placebo −8.5 −11.3 −10.1 −11.3 – – –
 SF-36 bodily pain, mean change from baselineb
  Secukinumab 300 mg – 18.4**** 18.2* 23.8**** 23.9 24.4 24.2
  Secukinumab 150 mg – 18.9**** 20.0*** 25.4**** 25.7 25.8 22.2
  Placebo – 5.6 7.3 8.6 – – –
 EQ-5D-3 L, no pain or discomfortc
  Secukinumab 300 mg – – – 21.5% 24.6% 28.6% 32.8%
  Secukinumab 150 mg – – – 22.2% 14.8% 20.3% 17.0%
  Placebo – – – 6.9% – – –
TNF-IR
 Pain VAS, mean change from baselined
  Secukinumab 300 mg −13.1** −14.9 −16.8** −18.2** −20.7 −22.5 −19.3
  Secukinumab 150 mg −14.8* −21.3* −21.2* −21.1* − 20.0 −23.9 − 20.4
  Placebo −2.1 −5.9 −3.4 −4.4 – – –
 SF-36 bodily pain, mean change from baselinee
  Secukinumab 300 mg – 15.1 18.7* 18.3* 23.6 23.0 24.5
  Secukinumab 150 mg – 13.6 21.0*** 17.9* 16.0 19.0 14.0
  Placebo – 7.8 5.7 5.2 – – –
 EQ-5D-3 L, no pain or discomfortf
  Secukinumab 300 mg – – – 12.5% 12.5% 15.6% 17.2%
  Secukinumab 150 mg – – – 10.8% 5.9% 20.0% 12.5%
  Placebo – – – 3.3% – – –
  1. Least squares mean change using a mixed-effect model for repeated measures (MMRM) from weeks 1 to 24, and observed data from weeks 52 to 104, for pain visual analog scale (VAS) and Short Form-36 (SF-36) bodily pain scores. Observed data are presented for the EuroQoL 5-Dimension 3-Level Questionnaire (EQ-5D-3 L). At week 16, patients initially randomized to placebo who were non-responders switched to secukinumab treatment. Results are not shown for patients who continued on placebo after week 16. Data are presented only for evaluable patients at each time point. TNF-naïve patients originally randomized to secukinumab 300 mg = 67, to secukinumab 150 mg = 63, and to placebo = 63; patients with inadequate response to TNF (TNF-IR) originally randomized to secukinumab 300 mg = 33, to secukinumab 150 mg = 37, and to placebo = 35. P values were calculated from a MMRM analysis
  2. aNumber of evaluable patients, week 52: 59 for secukinumab 300 mg and 150 mg; week 104: 57 for secukinumab 300 mg and 53 for secukinumab 150 mg
  3. bNumber of evaluable patients, week 52: 62 for secukinumab 300 mg and 59 for secukinumab 150 mg; week 104: 57 for secukinumab 300 mg and 53 for secukinumab 150 mg
  4. cNumber of evaluable patients, week 52: 63 for secukinumab 300 mg and 59 for secukinumab 150 mg; week 104: 58 for secukinumab 300 mg and 53 for secukinumab 150 mg
  5. dNumber of evaluable patients, week 52: 30 for secukinumab 300 mg and 29 for secukinumab 150 mg; week 104: 29 for secukinumab 300 mg and 24 for secukinumab 150 mg
  6. eNumber of evaluable patients, week 52: 32 for secukinumab 300 mg and 30 for secukinumab 150 mg; week 104: 29 for secukinumab 300 mg and 26 for secukinumab 150 mg
  7. fNumber of evaluable patients, week 52: 32 for secukinumab 300 mg and 30 for secukinumab 150 mg; week 104: 29 for secukinumab 300 mg and 24 for secukinumab 150 mg
  8. *P < 0.01; **P < 0.05; ***P < 0.001; ****P < 0.0001, versus placebo. TNF, tumor necrosis factor
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us